Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment

The absence of potent therapeutic option accounts for the dismal prognosis of advanced hepatocellular carcinoma (HCC) with high mortality and recurrence rate. For a decade, sorafenib is the only approved systemic drug in the first-line setting and warrants as the standard-of-care for HCC in the adva...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Transl Gastroenterol Hepatol
Huvudupphovsmän: Siu, Elaine Hon-Lam, Chan, Anthony Wing-Hung, Chong, Charing Ching-Ning, Chan, Stephen Lam, Lo, Kwok-Wai, Cheung, Siu Tim
Materialtyp: Artigo
Språk:Inglês
Publicerad: AME Publishing Company 2018
Ämnen:
Review Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286919/
https://ncbi.nlm.nih.gov/pubmed/30603725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tgh.2018.10.16
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk